Literature DB >> 29360526

Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.

Melanie C Dispenza1, Jacqueline A Pongracic2, Anne M Singh2, Bruce S Bochner3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29360526      PMCID： PMC7297295          DOI： 10.1016/j.jaci.2017.12.987

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects.

Authors:  F E Simons; J L McMillan; K J Simons
Journal:  J Allergy Clin Immunol       Date:  1990-10       Impact factor: 10.793

2.  Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.

Authors:  Melanie C Dispenza; Jennifer A Regan; Bruce S Bochner
Journal:  Expert Rev Clin Immunol       Date:  2017-08-31       Impact factor: 4.473

3.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Authors:  Donald MacGlashan; Lee A Honigberg; Ashley Smith; Joseph Buggy; John T Schroeder
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

Review 4.  Combining anti-IgE with oral immunotherapy.

Authors:  Chunrong Lin; Ivan T Lee; Vanitha Sampath; Chitra Dinakar; Rosemarie H DeKruyff; Lynda C Schneider; Kari Christine Nadeau
Journal:  Pediatr Allergy Immunol       Date:  2017-09-07       Impact factor: 6.377

5.  Absence of Tec family kinases interleukin-2 inducible T cell kinase (Itk) and Bruton's tyrosine kinase (Btk) severely impairs Fc epsilonRI-dependent mast cell responses.

Authors:  Archana S Iyer; J Luis Morales; Weishan Huang; Folake Ojo; Gang Ning; Elizabeth Wills; Joel D Baines; Avery August
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

6.  Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.

Authors:  Jennifer A Regan; Yun Cao; Melanie C Dispenza; Shuo Ma; Leo I Gordon; Adam M Petrich; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-04-04       Impact factor: 10.793

7.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

8.  The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells.

Authors:  Hye Sun Kuehn; Emily J Swindle; Mi-Sun Kim; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis.

Authors:  Peter Korosec; Paul J Turner; Mira Silar; Peter Kopac; Mitja Kosnik; Bernhard F Gibbs; Mohamed H Shamji; Adnan Custovic; Matija Rijavec
Journal:  J Allergy Clin Immunol       Date:  2017-03-22       Impact factor: 10.793
  9 in total
  15 in total

1.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Current and emerging treatments for chronic spontaneous urticaria.

Authors:  Kirti J Johal; Sarbjit S Saini
Journal:  Ann Allergy Asthma Immunol       Date:  2019-09-05       Impact factor: 6.347

3.  Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.

Authors:  Melanie C Dispenza; Rebecca A Krier-Burris; Krishan D Chhiba; Bradley J Undem; Piper A Robida; Bruce S Bochner
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

4.  Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge.

Authors:  Shiteng Duan; Britni M Arlian; Corwin M Nycholat; Yadong Wei; Hiroaki Tateno; Scott A Smith; Matthew S Macauley; Zhou Zhu; Bruce S Bochner; James C Paulson
Journal:  J Immunol       Date:  2021-04-28       Impact factor: 5.422

Review 5.  Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics.

Authors:  Nicole Ramsey; M Cecilia Berin
Journal:  Pediatr Allergy Immunol       Date:  2021-06-17       Impact factor: 5.464

Review 6.  Emerging Therapies in Chronic Spontaneous Urticaria.

Authors:  Taek Ki Min; Sarbjit S Saini
Journal:  Allergy Asthma Immunol Res       Date:  2019-07       Impact factor: 5.764

Review 7.  Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.

Authors:  Melanie C Dispenza; Bruce S Bochner; Donald W MacGlashan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 8.  The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.

Authors:  Melanie C Dispenza
Journal:  Curr Treat Options Allergy       Date:  2021-04-16

Review 9.  Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Petri T Kovanen; Emir Hadzijusufovic; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; K Frank Austen; Dean D Metcalfe; Stephen J Galli
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556

10.  Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Authors:  Tobias Litzenburger; Jürgen Steffgen; Ewald Benediktus; Fabian Müller; Armin Schultz; Elliott Klein; Meera Ramanujam; Christian Harcken; Alpana Gupta; Jing Wu; Sabrina Wiebe; Xiujiang Li; Mary Flack; Steven J Padula; Sudha Visvanathan; Andreas Hünnemeyer; Jianan Hui
Journal:  Br J Clin Pharmacol       Date:  2020-11-20       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.